Novartis to acquire 85% of Chinese vaccines company Zhejiang Tianyuan
NVS | Quote | Chart | News | PowerRating -- Swiss pharmaceutical company Novartis (VTX:NOVN) reported on Wednesday
that it has entered into an agreement to acquire an 85% stake in
Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co Ltd
for approximately USD125m.
Novartis said that this is in line with its strategy to grow in the
vaccines industry in China.
The two companies intend to collaborate on building a vaccines industry
leader targeting unmet medical needs in China.
The acquisition remains subject to government and regulatory approvals
in China.
Comments on this story may be sent to admin@m2.com
For full details on Novartis Ag Ads (NVS) NVS. Novartis Ag Ads (NVS) has Short Term PowerRatings at TradingMarkets. Details on Novartis Ag Ads (NVS) Short Term PowerRatings is available at This Link.
- Debiopharm Group signs agreement with Novartis for Debio 025 - 02/09/10
- SciClone and Sigma-Tau reports positive results from influenza vaccine study - 02/09/10
- Debiopharm Group signs licensing agreement with Novartis for Debio 025 for hepatitis C - 02/09/10
- Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025 - 02/09/10
- Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis - 02/09/10
- More News >>


